— Know what they know.
Not Investment Advice

OBIO NASDAQ

Orchestra BioMed Holdings, Inc.
1W: +29.1% 1M: +38.5% 3M: +50.4% YTD: +42.0% 1Y: +134.5% 3Y: -8.9% 5Y: -38.8%
$6.12
+0.31 (+5.34%)
 
Weekly Expected Move ±12.8%
$5 $5 $6 $7 $8
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 70 · $366.5M mcap · 41M float · 0.780% daily turnover · Short 48% of daily vol
Smart Money Score
Bullish 75
Insider+$0.2M
Congress
ETF Holdings
Key Statistics
Market Cap$366.5M
52W Range2.2-6.2499
Volume464,419
Avg Volume321,667
Beta0.53
Dividend
Analyst Ratings
6 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEODavid Hochman
Employees86
SectorHealthcare
IndustryBiotechnology
IPO Date2020-08-04
150 Union Square Drive
New Hope, PA 18938
US
215 862 5797
About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Hochman David P F-InKind 3,283 $5.81 2026-09-10
Hochman David P F-InKind 3,283 $5.81 2026-09-10
Hochman David P P-Purchase 10,000 $4.79 2026-09-03
Sherman Darren S-Sale 15,000 $4.94 2026-09-01
Taylor Andrew Lawren F-InKind 3,076 $5.26 2026-08-26

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms